R&D The future of precision psychiatry The mental health clinical trials market is expected to double to $4.27 billion in 2028, up from $2.15 billion in 2018, and
Events Partner Content International Neurology Conference Neurology-2018 welcomes you all to esteemed conference
News Vasopharm drug could limit damage caused by brain injuries German biotech moves into phase 3 after a long wait
News EU clears first drug therapy for rare disease cALD Neuraxpharm and Minoryx' Nezglyal has become the first approved drug therapy in the EU for rare neurodegenerative disease cALD.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
